Featured post

SCS research and awards news

For all our research and awards news, please visit our news page.

Showing posts with label melissa southey. Show all posts
Showing posts with label melissa southey. Show all posts

Monday, 18 December 2023

Tools of the Trade

Prof Melissa Southey
Professor Melissa Southey is to receive $50,000 from NHMRC Equipment Grant funding to go towards purchasing a TubeWriter 400, which is a full-feature labelling system for printing on curved surfaces, including tubes, vials, slides, plates, and custom labware. The TubeWriter 400 is used in labs all over the world, including in police investigations.  

Dr Sarah Marshall

Dr Sarah Marshall is also to receive $50,000 from NHMRC Equipment Grant funding. Sarah will purchase a wire myograph, which is the gold standard in measuring the function of isolated blood vessels with high precision and sensitivity. The equipment is extremely versatile and allows for the investigation of endothelial and smooth muscle mediated constriction and relaxation. Sarah said, “I will use the myograph to investigate the vascular dysfunction underpinning common pregnancy disorders including preeclampsia and gestational diabetes, and use it to assess potential therapeutics to protect and improve blood vessel function.”

Congratulations Melissa and Sarah. 

Tuesday, 13 October 2020

Genetic risk factors identified for prostate cancer


Monash University’s Precision Medicine research group has discovered multiple new genetic risk factors that make men susceptible to aggressive prostate cancer that will contribute to future prevention of the disease.  Read full story here.

Thursday, 3 October 2019

Professor Melissa Southey receives prostate cancer funding

Professor Melissa Southey

Professor Melissa Southey from the Department of Medicine is one of two Monash researchers to receive funding for research into prostate cancer. Last month, the Prostate Cancer Foundation of Australia announced more than $1 million in new funding to coincide with Prostate Cancer Awareness Month.

Monday, 29 October 2018

Monash to lead a new generation of medical research with the launch of Biobanking Victoria

Professor Melissa Southey
A brand new Monash University-led initiative, Biobanking Victoria will change the way researchers can translate discoveries into practice at hospitals and via clinical trials, thanks to a $1.5 million funding boost from the Victorian Government.

Monday, 24 September 2018

Professor Melissa Southey delivers prestigious Jass Memorial Lecture

Professor Melissa Southey receives
 the 'Jass Memorial Lecture Microscope'
from Professor John Hopper

Monash University’s Chair of Precision Medicine, Professor Melissa Southey was invited to deliver the highly prestigious Jass Memorial Lecture at the Familial Aspects of Cancer: Research and Practice scientific meeting in Kingscliff, NSW earlier this month.

Monday, 19 March 2018

Monday, 5 March 2018

Familial breast cancer not only inherited genetically, finds new study

Professor Melissa Southey
Doctors will be better able to predict breast cancer risk thanks to pioneering work led by Professor Melissa Southey, now Chair of Precision Medicine at Monash University. The study has identified heritable but non-genetic markers for breast cancer susceptibility.

Mutations in known breast cancer genes such as BRCA1 and BRCA2 are identified in only approximately 20 per cent of women who are offered genetic testing for familial breast cancer.

Professor Southey led a team of researchers who studied 210 people from 25 multiple case breast cancer families. They identified 24 previously unknown epigenetic changes that alter a woman’s risk of breast cancer and can be passed down through generations without involving changes in the DNA sequence of genes.

“For the majority of women who undergo genetic testing, there is no explanation for their breast cancer predisposition,” said Professor Southey, also from the Department of Clinical Pathology at the University of Melbourne.

“This ground-breaking work is not only helpful for women from families with many cases of breast cancer, it will improve breast cancer risk prediction for all women, and pave the way for the development of epigenetic therapeutics for breast cancer.”

The study, published in Nature Communications, looks at epigenetic changes called DNA methylation, where methyl group chemicals modify DNA without changing its sequence. DNA methylation can mimic genetic variation, predisposing a family to breast cancer. The study is one of the first to systematically scan the genome for places where DNA methylation is heritable, and is the first to apply this to familial breast cancer.

University of Melbourne statistician Dr James Dowty said: “Our methods were very successful when applied to breast cancer, and the exciting thing is that they can be applied to many other hereditary diseases. This work was the result of a very fruitful collaboration between molecular biologists and statisticians, like a lot of work in modern medical research.”

Monash University and University of Melbourne research fellow Dr Eric Joo said: “Some individuals know they come from a family with a lot of breast cancer but do not have a mutation in a known breast cancer gene. This study should help answer why some of those families have a lot of cancer. It’s very exciting to be unlocking part of a big puzzle.”

Researchers from the Cancer Council Victoria’s Division Cancer Epidemiology & Intelligence Division and The University of Utah also contributed to the work.